➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Dow

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CALCITONIN SALMON RECOMBINANT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Calcitonin Salmon Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004358 ↗ Phase II Study of Calcitonin for Tumoral Calcinosis Completed Ann & Robert H Lurie Children's Hospital of Chicago Phase 2 1992-11-01 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
NCT00004358 ↗ Phase II Study of Calcitonin for Tumoral Calcinosis Completed National Center for Research Resources (NCRR) Phase 2 1992-11-01 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
NCT00239889 ↗ Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women Completed Novartis Phase 4 2002-03-01 Calcitonin has been used for many years for treating osteoporosis in postmenopausal women, and it has been shown that calcitonin reduces pain after spine and hip fracture in women with osteoporosis. Therefore, this study assesses the safety and efficacy of salmon calcitonin nasal spray on muscle strength after a forearm fracture, pain, quality of life and fracture healing in postmenopausal women.
NCT00372099 ↗ Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women Completed Rene Rizzoli Phase 3 2007-01-01 Calcitonin has been used for many years for treating osteoporosis in postmenopausal women. Recent data from the 2 years placebo-controlled QUEST study have shown a preservation of microarchitecture as measured by high resolution MRI in postmenopausal women with prevalent vertebral fractures at baseline.This pilot study should provide additional new insights in the mode of action of nasal calcitonin, on structural changes as measured by high resolution peripheral CT, and on the comparison between weight bearing and non weight bearing bones in postmenopausal women.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Calcitonin Salmon Recombinant

Condition Name

Condition Name for Calcitonin Salmon Recombinant
Intervention Trials
Osteoarthritis 4
Osteoporosis 3
Postmenopausal Osteoporosis 2
Osteoporosis, Postmenopausal 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Calcitonin Salmon Recombinant
Intervention Trials
Osteoporosis 10
Osteoporosis, Postmenopausal 7
Osteoarthritis 4
Osteoarthritis, Knee 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Calcitonin Salmon Recombinant

Trials by Country

Trials by Country for Calcitonin Salmon Recombinant
Location Trials
United States 30
United Kingdom 7
Denmark 7
Poland 4
Czech Republic 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Calcitonin Salmon Recombinant
Location Trials
Missouri 4
California 3
Wisconsin 2
Pennsylvania 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Calcitonin Salmon Recombinant

Clinical Trial Phase

Clinical Trial Phase for Calcitonin Salmon Recombinant
Clinical Trial Phase Trials
Phase 4 4
Phase 3 9
Phase 2 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Calcitonin Salmon Recombinant
Clinical Trial Phase Trials
Completed 17
Terminated 2
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Calcitonin Salmon Recombinant

Sponsor Name

Sponsor Name for Calcitonin Salmon Recombinant
Sponsor Trials
Novartis 9
Eli Lilly and Company 4
Tarsa Therapeutics, Inc. 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Calcitonin Salmon Recombinant
Sponsor Trials
Industry 21
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.